These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10080218)

  • 1. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.
    Kotake S; Higashi K; Yoshikawa K; Sasamoto Y; Okamoto T; Matsuda H
    Ophthalmology; 1999 Mar; 106(3):586-9. PubMed ID: 10080218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE; Perry HD
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A.
    Kato Y; Numaga J; Kato S; Kaburaki T; Kawashima H; Fujino Y
    Clin Exp Ophthalmol; 2001 Oct; 29(5):335-6. PubMed ID: 11720163
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
    Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behçet Disease (ABD).
    Boura P; Tselios K; Kamali S; Skendros P; Sarantopoulos A; Topouzis F
    Neurol Sci; 2006 Dec; 27(6):432-5. PubMed ID: 17205230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The involvement of the parenchyma of the central nervous system in Behçet disease].
    Martínez-Yélamos A; Vidaller A; Mitjavila F; Pujol R; Jato M; Rubio F
    Rev Neurol; 1998 Aug; 27(156):223-5. PubMed ID: 9736951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine-induced white and grey matter central nervous system lesions in a pediatric renal transplant patient.
    Jeruss J; Braun SV; Reese JC; Guillot A
    Pediatr Transplant; 1998 Feb; 2(1):45-50. PubMed ID: 10084760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine.
    Sloper CM; Powell RJ; Dua HS
    Ophthalmology; 1999 Apr; 106(4):723-8. PubMed ID: 10201592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of patients with Behçet's disease in the 1980s and 1990s.
    Yoshida A; Kawashima H; Motoyama Y; Shibui H; Kaburaki T; Shimizu K; Ando K; Hijikata K; Izawa Y; Hayashi K; Numaga J; Fujino Y; Masuda K; Araie M
    Ophthalmology; 2004 Apr; 111(4):810-5. PubMed ID: 15051217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular findings after allogeneic hematopoietic stem cell transplantation.
    Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
    Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uveitis associated with pediatric behçet disease in the american midwest.
    Kesen MR; Goldstein DA; Tessler HH
    Am J Ophthalmol; 2008 Dec; 146(6):819-27.e2. PubMed ID: 18672222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.
    de Groen PC; Aksamit AJ; Rakela J; Forbes GS; Krom RA
    N Engl J Med; 1987 Oct; 317(14):861-6. PubMed ID: 3306386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Behçet disease].
    Dogan D; Farah C
    Oftalmologia; 2002; 52(1):23-30. PubMed ID: 12677795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases.
    Kötter I; Günaydin I; Batra M; Vonthein R; Stübiger N; Fierlbeck G; Melms A
    Clin Rheumatol; 2006 Jul; 25(4):482-6. PubMed ID: 16261281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ciclosporin-associated cerebral tumor-like location of Behçet's disease].
    Bouomrani S; Hammami S; Braham R; Mahjoub S
    Rev Neurol (Paris); 2010 Oct; 166(10):849-54. PubMed ID: 20346476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early central nervous system complications after reduced-intensity stem cell transplantation.
    Kishi Y; Miyakoshi S; Kami M; Ikeda M; Katayama Y; Murashige N; Kusumi E; Yuji K; Kobayashi K; Kato D; Hamaki T; Matsumura T; Kim SW; Morinaga S; Mori S; Kanemaru M; Hayashi T; Takaue Y; Taniguchi S;
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):561-8. PubMed ID: 15282534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.